FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3036003532> ?p ?o ?g. }

• W3036003532 endingPage "625" @default.
• W3036003532 startingPage "622" @default.
• W3036003532 abstract "The “coronavirus disease 2019 (COVID-19)” outbreak was first reported in December 2019 (China). Since then, this disease has rapidly spread across the globe and in March 2020 the World Health Organization (WHO) declared the COVID-19 pandemic.1 Since the outbreak was first announced, our journal has extensively focused on the clinical features, outcomes, diagnosis, immunology, and pathogenesis of COVID-19 and its infectious agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We published our first COVID-19 article on 19 February, focusing for the first time on the clinical characteristics of 140 cases of human-to-human coronavirus transmission without any links to the Huanan Wet Market.2 Hypertension and diabetes were mentioned as risk factors and there was no increased prevalence in allergic patients. This early study reported that the main symptoms at hospital admission were fever (91.7%), cough (75.0%), fatigue (75.0%), gastrointestinal symptoms (39.6%), and dyspnea (36.7%). Lymphopenia and eosinopenia were also reported as important signs and biomarkers for monitoring and severity of the patients.2 The prevalent eosinopenia in COVID-19 patients and the possible anti-viral role of eosinophils were further discussed in several following publications in Allergy.3, 4 Our second COVID-19 paper brought attention to the wide range of clinical manifestations of this disease, from asymptomatic cases to patients with mild and severe symptoms, with or without pneumonia as well as with only diarrhea.5 Patients with common allergic diseases did not develop distinct symptoms and severe courses. Cases with pre-existing chronic obstructive pulmonary disease or complicated with a secondary bacterial pneumonia were severe. Another article, timely appearing in our journal, alerted the scientific community that even in experienced hands there was a 14.1% false-negative polymerase chain reaction (PCR) diagnosis in COVID-19 cases and were later diagnosed positive after repeated tests.6 A pediatric article was also published extensively analyzing 182 cases, and it was reported that children with COVID-19 showed a mild clinical course.7 Patients with pneumonia had a higher proportion of fever and cough and increased inflammatory biomarkers compared to those without pneumonia. There were 43 allergic patients in this series, and there was no significant difference between allergic and nonallergic COVID-19 children in disease incidence, clinical features, laboratory, and immunological findings. Allergy was not a risk factor for disease and severity of SARS-CoV-2 infection and did not significantly influence the disease course of COVID-19 in children.7 The immunology of COVID-19 was extensively reviewed in two articles from leading experts with a comprehensive discussion of the tip of the iceberg in COVID-19 epidemiology, anti-viral response, antibody response to SARS-CoV-2, acute phase reactants, cytokine storm, and pathogenesis of tissue injury and severity.8, 9 Two studies timely reported the role of possible trained immunity in countries with a Bacillus Calmette-Guérin (BCG) vaccination program and a relatively low COVID-19 prevalence and mortality rate.10, 11 In an extensive RNA sequencing analyses of SARS-CoV-2 receptor and their molecular partners revealed that ACE2 and TMPRSS2 were coexpressed at the epithelial sites of the lung and skin, whereas CD147 (BSG), cyclophilins (PPIA and PPIB), CD26 (DPP4) and related molecules were expressed in both, epithelium and in immune cells.12 Allergists, respiratory physicians, pediatricians, and other healthcare providers treating patients with allergic diseases are frequently in contact with patients potentially infected with SARS-CoV-2. Practical considerations and recommendations given by experts in the field of allergic diseases can provide useful recommendations for clinical daily work. Since the beginning of this current pandemic, our journal has disseminated clinical reports,2, 3, 5, 6, 13 statements on the urgent need for accuracy in designing and reporting clinical trials in COVID-19,14 preventive measures,10, 11, 15 and Position Statements elaborated by experts in the field in close collaboration with the European Academy of Allergy and Clinical Immunology (EAACI) and the organization “Allergy and Its Impact on Asthma (ARIA)”.16-25, 27 (keynote information in Table 1). A compendium answering 150 frequently encountered questions regarding COVID-19 and allergic diseases has been recently published by experts in their respective area (Figure 1).28 In addition, readers can put further questions regarding this “living” compendium electronically to the authors and their answers will be available through a new category in the journal's web page.29 Besides, EAACI in collaboration with ARIA, has provided recommendations on operational plans and practical procedures for ensuring optimal standards in the daily clinical care of patients with allergic diseases, while ensuring the safety of patients and healthcare workers.23 Intranasal corticosteroids (including nasal sprays) can be further applied in COVID-19 patients at the recommended dosages, and a cessation or interruption is not recommended Furthermore, a cessation or interruption of allergen immunotherapy (AIT) for both the subcutaneous route (SCIT) or sublingual route (SLIT) is not recommended in asymptomatic patients without suspicion for SARS-CoV-2 infection and/or contact to SARS-CoV-2 positive individuals or in other conditions as outlined Intranasal corticosteroids in allergic rhinitis in COVID-19-infected patients: An ARIA-EAACI statement21 Handling of allergen immunotherapy in the COVID-19 pandemic: An ARIA-EAACI statement22 Biologicals should be applied in type 2 inflammations (asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria) via self-application in noninfected patients In patient with an active SARS-CoV-2 infection treatment with biologicals should be paused and re-initiated after recovery and SARS-CoV-2 negativity of patients Less severe courses of COVID-19 in the pediatric population have been reported Similar to the adult age group, severe forms of asthma and immunodeficiencies are reported to be risk factors A sufficient control of symptoms in children with allergies, asthma and immunodeficiency in accordance with current guidelines is key in the current pandemic Drugs being used in different phases of COVID-19 disease seem to cause rare but potentially severe drug hypersensitivity reactions (DHRs) Most of these DHRs affect the skin and are nonimmediate The most important differential diagnosis of these DHRs is COVID-19-related exanthems An international survey revealed that experts in the field recommend that during the ongoing pandemic therapy strategies in line with current guidelines should be followed However, particular caution for the use of corticosteroids and immunomodulators in COVID-19-infected patients is expressed Recommendations on operational plans and procedures to maintain high standards in the daily clinical care of allergic patients while ensuring necessary safety in the current COVID-19 pandemic should be followed Nine different scenarios and topics are discussed Even though there has been a decrease in both infection rates and prevalence of COVID-19 in some parts of the world, in some countries the spread of COVID-19 has not been adequately controlled and the numbers are still rising. Epidemiologists have warned of possible subsequent waves until an effective vaccination becomes available. Until then, recommendations for different aspects of patient care are strictly needed, which underlines the importance of the COVID-19 series of publications in this journal. The recommendations provided in these articles will inform allergists and healthcare providers on the management and treatment of patients during this pandemic. It should be noted that these statements are based on current evidence and medical knowledge and there is a paucity of prospective clinical trials regarding some of the information provided in these documents. These clinical statements need to be regularly updated with incoming new clinical data. Dr Pfaar reports grants and/or personal fees from ALK-Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding BV/HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, Biomay, Circassia, ASIT Biotech Tools SA, Laboratorios LETI/LETI Pharma, MEDA Pharma/MYLAN, Anergis SA, Mobile Chamber Experts (a GA2LEN Partner), Indoor Biotechnologies, GSK, Astellas Pharma Global, EUFOREA, ROXALL, NOVARTIS, SANOFI AVENTIS, Med Update Europe GmbH, and streamedup! GmbH. Dr Torres has no conflict of interest in relation to this work. Dr Akdis reports grants from Allergopharma, Idorsia, Swiss National Science Foundation, Christine Kühne-Center for Allergy Research and Education, European Commission's Horizon's 2020 Framework Programme, Cure, Novartis Research Institutes, AstraZeneca, SciBase, GSK, and other from Sanofi and Regeneron." @default.
• W3036003532 created "2020-06-25" @default.
• W3036003532 creator A5034364156 @default.
• W3036003532 creator A5055404517 @default.
• W3036003532 creator A5084503790 @default.
• W3036003532 date "2021-03-01" @default.
• W3036003532 modified "2023-10-07" @default.
• W3036003532 title "COVID‐19: A series of important recent clinical and laboratory reports in immunology and pathogenesis of SARS‐CoV‐2 infection and care of allergy patients" @default.
• W3036003532 cites W3007814559 @default.
• W3036003532 cites W3011971686 @default.
• W3036003532 cites W3013250171 @default.
• W3036003532 cites W3013494042 @default.
• W3036003532 cites W3015639758 @default.
• W3036003532 cites W3016319005 @default.
• W3036003532 cites W3016559120 @default.
• W3036003532 cites W3019441938 @default.
• W3036003532 cites W3020310739 @default.
• W3036003532 cites W3020781652 @default.
• W3036003532 cites W3022409605 @default.
• W3036003532 cites W3023601074 @default.
• W3036003532 cites W3024012792 @default.
• W3036003532 cites W3024541652 @default.
• W3036003532 cites W3024614908 @default.
• W3036003532 cites W3024615678 @default.
• W3036003532 cites W3029533207 @default.
• W3036003532 cites W3032838347 @default.
• W3036003532 cites W3033058197 @default.
• W3036003532 cites W3033178045 @default.
• W3036003532 cites W3033402428 @default.
• W3036003532 cites W3034588094 @default.
• W3036003532 cites W3034723589 @default.
• W3036003532 cites W3036031606 @default.
• W3036003532 cites W3037412157 @default.
• W3036003532 cites W3038019244 @default.
• W3036003532 cites W3093025606 @default.
• W3036003532 doi "https://doi.org/10.1111/all.14472" @default.
• W3036003532 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7361446" @default.
• W3036003532 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32589296" @default.
• W3036003532 hasPublicationYear "2021" @default.
• W3036003532 type Work @default.
• W3036003532 sameAs 3036003532 @default.
• W3036003532 citedByCount "11" @default.
• W3036003532 countsByYear W30360035322020 @default.
• W3036003532 countsByYear W30360035322021 @default.
• W3036003532 countsByYear W30360035322022 @default.
• W3036003532 countsByYear W30360035322023 @default.
• W3036003532 crossrefType "journal-article" @default.
• W3036003532 hasAuthorship W3036003532A5034364156 @default.
• W3036003532 hasAuthorship W3036003532A5055404517 @default.
• W3036003532 hasAuthorship W3036003532A5084503790 @default.
• W3036003532 hasBestOaLocation W30360035321 @default.
• W3036003532 hasConcept C116675565 @default.
• W3036003532 hasConcept C142724271 @default.
• W3036003532 hasConcept C159047783 @default.
• W3036003532 hasConcept C203014093 @default.
• W3036003532 hasConcept C207480886 @default.
• W3036003532 hasConcept C2779134260 @default.
• W3036003532 hasConcept C2780942790 @default.
• W3036003532 hasConcept C2994571964 @default.
• W3036003532 hasConcept C3006700255 @default.
• W3036003532 hasConcept C3007834351 @default.
• W3036003532 hasConcept C3008058167 @default.
• W3036003532 hasConcept C524204448 @default.
• W3036003532 hasConcept C71924100 @default.
• W3036003532 hasConcept C89623803 @default.
• W3036003532 hasConceptScore W3036003532C116675565 @default.
• W3036003532 hasConceptScore W3036003532C142724271 @default.
• W3036003532 hasConceptScore W3036003532C159047783 @default.
• W3036003532 hasConceptScore W3036003532C203014093 @default.
• W3036003532 hasConceptScore W3036003532C207480886 @default.
• W3036003532 hasConceptScore W3036003532C2779134260 @default.
• W3036003532 hasConceptScore W3036003532C2780942790 @default.
• W3036003532 hasConceptScore W3036003532C2994571964 @default.
• W3036003532 hasConceptScore W3036003532C3006700255 @default.
• W3036003532 hasConceptScore W3036003532C3007834351 @default.
• W3036003532 hasConceptScore W3036003532C3008058167 @default.
• W3036003532 hasConceptScore W3036003532C524204448 @default.
• W3036003532 hasConceptScore W3036003532C71924100 @default.
• W3036003532 hasConceptScore W3036003532C89623803 @default.
• W3036003532 hasIssue "3" @default.
• W3036003532 hasLocation W30360035321 @default.
• W3036003532 hasLocation W30360035322 @default.
• W3036003532 hasLocation W30360035323 @default.
• W3036003532 hasLocation W30360035324 @default.
• W3036003532 hasLocation W30360035325 @default.
• W3036003532 hasLocation W30360035326 @default.
• W3036003532 hasLocation W30360035327 @default.
• W3036003532 hasOpenAccess W3036003532 @default.
• W3036003532 hasPrimaryLocation W30360035321 @default.
• W3036003532 hasRelatedWork W3017171836 @default.
• W3036003532 hasRelatedWork W3025176011 @default.
• W3036003532 hasRelatedWork W3027835066 @default.
• W3036003532 hasRelatedWork W3032320397 @default.
• W3036003532 hasRelatedWork W3033635008 @default.
• W3036003532 hasRelatedWork W3152606407 @default.
• W3036003532 hasRelatedWork W4280491013 @default.
• W3036003532 hasRelatedWork W4308017287 @default.
• W3036003532 hasRelatedWork W3107152225 @default.

• next